Trial Profile

A Phase I Trial of the IGF-1R Antibody AMG 479 in Combination With Everolimus (RAD001) and Panitumumab in Patients With Advanced Cancer (The RAP Trial).

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 08 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Everolimus (Primary) ; Ganitumab (Primary) ; Panitumumab (Primary)
Indications Adenocarcinoma; Chondrosarcoma; Colorectal cancer; Head and neck cancer; Neuroendocrine tumours; Non-small cell lung cancer; Sarcoma; Solid tumours
Focus Adverse reactions; Biomarker
Acronyms QUILT-3.007; RAP

Most Recent Events

26 Aug 2019 Status changed from active, no longer recruiting to completed.
30 Jul 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Jun 2019.
09 Feb 2018 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com